

Christian Grommes

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5977317/publications.pdf>

Version: 2024-02-01

54
papers

4,069
citations

201674

27
h-index

175258

52
g-index

55
all docs

55
docs citations

55
times ranked

5547
citing authors

#	ARTICLE	IF	CITATIONS
1	[89Zr]Zr-huJ591 immuno-PET targeting PSMA in IDH mutant anaplastic oligodendroglioma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 783-785.	6.4	4
2	Primary central nervous system lymphoma. <i>Blood</i> , 2022, 140, 971-979.	1.4	60
3	Primary Central Nervous System Lymphomas. <i>Hematology/Oncology Clinics of North America</i> , 2022, 36, 147-159.	2.2	10
4	Rituximab, Methotrexate, Carmustine, Etoposide, and Prednisone (RMBVP) for the treatment of relapsed/refractory primary central nervous system lymphoma: a retrospective single-center study. <i>Leukemia and Lymphoma</i> , 2022, 63, 627-632.	1.3	1
5	Routine use of low-dose glucarpidase following high-dose methotrexate in adult patients with CNS lymphoma: an open-label, multi-center phase I study. <i>BMC Cancer</i> , 2022, 22, 60.	2.6	5
6	Clinical trial of proton craniospinal irradiation for leptomeningeal metastases. <i>Neuro-Oncology</i> , 2021, 23, 134-143.	1.2	56
7	Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG). <i>Neuro-Oncology</i> , 2021, 23, 1056-1071.	1.2	68
8	Primary central nervous system lymphoma: a narrative review of ongoing clinical trials and goals for future studies. <i>Annals of Lymphoma</i> , 2021, 5, 8-8.	4.5	7
9	Prognostic value of [18F]FDG PET/CT in patients with CNS lymphoma receiving ibrutinib-based therapies. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3940-3950.	6.4	8
10	Positron emission tomography and magnetic resonance imaging in primary central nervous system lymphoma—a narrative review. <i>Annals of Lymphoma</i> , 2021, 5, 15-15.	4.5	13
11	Use of circulating tumor DNA to guide treatment of primary central nervous system lymphoma: a case report. <i>Neuro-Oncology Advances</i> , 2021, 3, v143.	0.7	2
12	Update on Novel Therapeutics for Primary CNS Lymphoma. <i>Cancers</i> , 2021, 13, 5372.	3.7	19
13	Central Nervous System Lymphoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2020, 26, 241-252.	2.0	12
14	Imaging CXCR4 Expression with Iodinated and Brominated Cyclam Derivatives. <i>Molecular Imaging and Biology</i> , 2020, 22, 1184-1196.	2.6	7
15	Randomized phase II study of rituximab, methotrexate (MTX), procarbazine, vincristine, and cytarabine (R-MPV-A) with and without low-dose whole-brain radiotherapy (LD-WBRT) for newly diagnosed primary CNS lymphoma (PCNSL).. <i>Journal of Clinical Oncology</i> , 2020, 38, 2501-2501.	1.6	29
16	Challenges in the Treatment of Newly Diagnosed and Recurrent Primary Central Nervous System Lymphoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 1571-1578.	4.9	31
17	Central Nervous System Lymphomas. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2020, 26, 1476-1494.	0.8	5
18	Genomic Correlates of Disease Progression and Treatment Response in Prospectively Characterized Gliomas. <i>Clinical Cancer Research</i> , 2019, 25, 5537-5547.	7.0	107

#	ARTICLE	IF	CITATIONS
19	Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid. <i>Nature</i> , 2019, 565, 654-658.	27.8	361
20	SL3 PRIMARY CNS LYMPHOMA: CURRENT CONCEPTS AND THERAPEUTIC PERSPECTIVES. <i>Neuro-Oncology Advances</i> , 2019, 1, ii4-ii4.	0.7	0
21	Molecular profiling of primary central nervous system lymphomas â€“ predictive and prognostic value?. <i>Current Opinion in Neurology</i> , 2019, 32, 886-894.	3.6	16
22	Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma. <i>Blood</i> , 2019, 133, 436-445.	1.4	159
23	Comprehensive approach to diagnosis and treatment of newly diagnosed primary CNS lymphoma. <i>Neuro-Oncology</i> , 2019, 21, 296-305.	1.2	114
24	Introduction of novel agents in the treatment of primary CNS lymphoma. <i>Neuro-Oncology</i> , 2019, 21, 306-313.	1.2	63
25	Staging identifies non-CNS malignancies in a large cohort with newly diagnosed lymphomatous brain lesions. <i>Leukemia and Lymphoma</i> , 2019, 60, 2278-2282.	1.3	15
26	Updates on Primary Central Nervous System Lymphoma. <i>Current Oncology Reports</i> , 2018, 20, 11.	4.0	37
27	The elderly left behindâ€”changes in survival trends of primary central nervous system lymphoma over the past 4 decades. <i>Neuro-Oncology</i> , 2018, 20, 687-694.	1.2	159
28	Treatment of Primary Central Nervous System Lymphoma: From Chemotherapy to Small Molecules. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 604-615.	3.8	28
29	Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphoma. <i>Blood</i> , 2018, 132, 2240-2248.	1.4	90
30	Pretreatment dynamic contrast-enhanced MRI biomarkers correlate with progression-free survival in primary central nervous system lymphoma. <i>Journal of Neuro-Oncology</i> , 2018, 140, 351-358.	2.9	21
31	Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma. <i>Cancer Discovery</i> , 2017, 7, 1018-1029.	9.4	302
32	Ibrutinib in PCNSL: The Curious Cases of Clinical Responses and Aspergillosis. <i>Cancer Cell</i> , 2017, 31, 731-733.	16.8	37
33	EGFR feedback-inhibition by Ran-binding protein 6 is disrupted in cancer. <i>Nature Communications</i> , 2017, 8, 2035.	12.8	23
34	Retrospective review of safety and efficacy of programmed cell death-1 inhibitors in refractory high grade gliomas. , 2017, 5, 99.		48
35	Primary CNS Lymphoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 2410-2418.	1.6	391
36	Changes in survival of primary central nervous system lymphoma based on a review of national databases over 40 years.. <i>Journal of Clinical Oncology</i> , 2017, 35, 2040-2040.	1.6	4

#	ARTICLE	IF	CITATIONS
37	Molecular and Clinical Effects of Notch Inhibition in Glioma Patients: A Phase 0/I Trial. <i>Clinical Cancer Research</i> , 2016, 22, 4786-4796.	7.0	95
38	Evaluating Cancer of the Central Nervous System Through Next-Generation Sequencing of Cerebrospinal Fluid. <i>Journal of Clinical Oncology</i> , 2016, 34, 2404-2415.	1.6	297
39	ACTR-11. PHASE II STUDY OF SINGLE AGENT BUPARLISIB IN RECURRENT/REFRACTORY PRIMARY (PCNSL) AND SECONDARY CNS LYMPHOMA (SCNSL). <i>Neuro-Oncology</i> , 2016, 18, vi3-vi3.	1.2	2
40	Posterior Reversible Encephalopathy Syndrome in Patients With Cancer. <i>Oncologist</i> , 2015, 20, 806-811.	3.7	88
41	Bevacizumab for the treatment of high-grade glioma: an update after Phase III trials. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 729-740.	3.1	41
42	Phase II Study of Bevacizumab, Temozolomide, and Hypofractionated Stereotactic Radiotherapy for Newly Diagnosed Glioblastoma. <i>Clinical Cancer Research</i> , 2014, 20, 5023-5031.	7.0	89
43	The PPAR γ agonist pioglitazone crosses the blood-brain barrier and reduces tumor growth in a human xenograft model. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 929-936.	2.3	60
44	Retrospective analysis of the effects of steroid therapy and antidiabetic medication on survival in diabetic glioblastoma patients. <i>CNS Oncology</i> , 2013, 2, 237-246.	3.0	30
45	Bevacizumab for the treatment of high-grade glioma. <i>Expert Opinion on Biological Therapy</i> , 2012, 12, 1101-1111.	3.1	23
46	Treatment of epidural spinal cord involvement from germ cell tumors with chemotherapy. <i>Cancer</i> , 2011, 117, 1911-1916.	4.1	10
47	"Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer. <i>Neuro-Oncology</i> , 2011, 13, 1364-1369.	1.2	309
48	The Stepping Test: A Step Back In History. <i>Journal of the History of the Neurosciences</i> , 2011, 20, 29-33.	0.9	17
49	Inverse association of PPAR γ agonists use and high grade glioma development. <i>Journal of Neuro-Oncology</i> , 2010, 100, 233-239.	2.9	30
50	Lambert-Eaton syndrome with large-cell neuroendocrine carcinoma of the lung. <i>Muscle and Nerve</i> , 2008, 37, 786-789.	2.2	9
51	Inhibition of in Vivo Glioma Growth and Invasion by Peroxisome Proliferator-Activated Receptor γ Agonist Treatment. <i>Molecular Pharmacology</i> , 2006, 70, 1524-1533.	2.3	98
52	The Nonthiazolidinedione Tyrosine-Based Peroxisome Proliferator-Activated Receptor γ Ligand GW7845 Induces Apoptosis and Limits Migration and Invasion of Rat and Human Glioma Cells. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005, 313, 806-813.	2.5	27
53	Antineoplastic effects of peroxisome proliferator-activated receptor γ agonists. <i>Lancet Oncology</i> , The, 2004, 5, 419-429.	10.7	413
54	Induction of apoptosis in human and rat glioma by agonists of the nuclear receptor PPAR γ . <i>Journal of Neurochemistry</i> , 2002, 81, 1052-1060.	3.9	119